USPTO serial 98139888
IMMUNOLIGHT
Reviewed by CopyMark Law Group
Status 733Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- VERHOSEK, WILLIAM T
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with IMMUNOLIGHT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,143*
Plus Government fees of $1,050
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
DETROIT, MI, US
DETROIT, MI, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
J. Derek Mason
J. Derek Mason TUCKER ELLIS LLP950 MAIN AVENUESUITE 1100CLEVELAND, OH 44113Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical additives for altering color in cosmetic preparations; substances in the nature of chemicals for use in solar cells and photovoltaic cells | ACTIVE | — |
| 002 | Powdered energy converting additives for altering color in paint, pigment, and colorant preparations; paint preparations in the nature of paints and coatings containing particulate energy converting additives; pigment preparations in the nature of pigments containing particulate energy converting additives; colorant preparations in the nature of colorants containing particulate energy converting additives. | ACTIVE | — |
| 003 | Additives for altering color in cosmetic preparations, namely, coloring preparations and non-medicated skin care preparations; cosmetic preparations | ACTIVE | — |
| 005 | Pharmaceutical preparations for biological tissue regeneration; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of inflammation; pharmaceutical preparations for the treatment of brain disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of autoimmune disease and disorders; pharmaceutical agents for treating a disease, condition, or disorder of the tissues of a subject by detecting and triggering biophotons; pharmaceutical agents for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intercellular communication; pharmaceutical agents for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intracellular communication; pharmaceutical preparations for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering biophotons; pharmaceutical preparations for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intercellular communication; pharmaceutical preparations for treating a disease, condition, and disorder of tissues of a subject by detecting and triggering intracellular communication; preparations for sanitization and remediation of air supply, water supply, and biological materials for medical purposes | ACTIVE | — |
| 009 | Energy storage systems comprised of solar cells, photovoltaic cells and modules and any combination thereof; optical fibers for light or color transmission; optical communication networks comprised of optical fibers | ACTIVE | — |
| 010 | Medical device for detection of biophotons; medical device for detection of intercellular communication; medical device for detection of intracellular communication; medical device for treating a disease, condition and disorder by detection of intercellular communication; medical device for treating a disease, condition and disorder by detection of intracellular communication; medical device for triggering of biophotons; medical device for detection of intercellular communication; medical device for triggering of intracellular communication; medical device for treating a disease, condition and disorder by triggering of intercellular communication; medical device for treating a disease, condition and disorder by triggering of intracellular communication | ACTIVE | — |
| 044 | Medical services for treating a disease, condition, or disorder by detection of intercellular communication; medical services for treating a disease, condition, or disorder by detection of intracellular communication; medical services for treating a disease, condition, or disorder by detection and propagation of intercellular communication; medical services for treating a disease, condition, or disorder by detection and propagation of intracellular communication; medical services for treating a disease, condition, or disorder by triggering of intercellular communication; medical services for treating a disease, condition, or disorder by triggering of intracellular communication; medical services for biological tissue regeneration; medical services for the treatment of pain; medical services for the treatment of inflammation; medical services for the treatment of brain disorders; medical services for the treatment of cancer; medical services for the treatment of autoimmune disease or disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Immunolight, LLC
- Other trademarks owned by Immunolight, LLC
- Other trademarks in Class 001
- Other trademarks in Class 002
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named IMMUNOLIGHT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 28, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 28, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 28, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 29, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 28, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 28, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 28, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 18, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 17, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 17, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 17, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 25, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 25, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 24, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 24, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 29, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 3, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 3, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 14, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 31, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 24, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 24, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 24, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 16, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 16, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 16, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 1, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jan 30, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Oct 31, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 26, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 18, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 22, 2023 | NWAP | NEW APPLICATION ENTERED | — |